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Abstract
Background: Prion diseases are fatal neurodegenerative disorders that accompany an accumulation of the disease-
associated form(s) of prion protein (PrP
Sc) in the central nervous system. The neuropathological changes in the
brain begin with focal deposits of PrP
Sc, followed by pathomorphological abnormalities of axon terminal
degeneration, synaptic loss, atrophy of dendritic trees, and eventual neuronal cell death in the lesions. However,
the underlying molecular basis for these neuropathogenic abnormalities is not fully understood.
Results: In a proteomic analysis of soluble proteins in the brains of mice challenged intracerebrally with scrapie
prion (Obihiro I strain), we found that the amount of the full-length form of collapsin response mediator protein-2
(CRMP-2; 61 kDa) decreased in the late stages of the disease, while the amount of its truncated form (56 kDa)
increased to comparable levels observed for the full-length form. Detailed analysis by liquid chromatography-
electrospray ionization-tandem mass spectrometry showed that the 56-kDa form (named CRMP-2-ΔC) lacked the
sequence from serine
518 to the C-terminus, including the C-terminal phosphorylation sites important for the
regulation of axonal growth and axon-dendrite specification in developing neurons. The invariable size of the
mRNA transcript in Northern blot analysis suggested that the truncation was due to post-translational proteolysis.
By overexpression of CRMP-2-ΔC in primary cultured neurons, we observed the augmentation of the development
of neurite branch tips to the same levels as for CRMP-2
T514A/T555A, a non-phosphorylated mimic of the full-length
protein. This suggests that the increased level of CRMP-2-ΔC in the brain modulates the integrity of neurons, and
may be involved in the pathogenesis of the neuronal abnormalities observed in the late stages of the disease.
Conclusions: We identified the presence of CRMP-2-ΔC in the brain of a murine model of prion disease. Of note,
C-terminal truncations of CRMP-2 have been recently observed in models for neurodegenerative disorders such as
ischemia, traumatic brain injury, and Wallerian degeneration. While the structural identity of CRMP-2-ΔC in those
models remains unknown, the present study should provide clues to the molecular pathology of degenerating
neurons in prion diseases in connection with other neurodegenerative disorders.
Background
Transmissible spongiform encephalopathies, or prion
diseases, are fatal neurodegenerative disorders that
include Creutzfeldt-Jakob disease, Gerstmann-Sträussler-
Scheinker disease, fatal familial insomnia and kuru in
humans, scrapie in sheep and goats, and bovine spongi-
form encephalopathy in cattle. The diseases are charac-
terized by the accumulation of the disease-associated
form(s) of prion protein (PrP
Sc) in the central nervous
system and neuronal loss and vacuolation, although
these features are not evident in some cases [1]. Ana-
lyses in murine models of scrapie showed that the neu-
ropathological changes begin with the local deposition
of PrP
Sc, followed by axon terminal degeneration,
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lesions [2,3]. PrP
Sc is a conformational isoform of the
cellular prion protein (PrP
C) encoded by the host prnp
gene. While PrP
C is susceptible to digestion by protei-
nase K (PK), PrP
Sc is partially resistant to PK and is
considered to be the infectious agent [1,4].
PrP
C is a glycosylphosphatidylinositol-anchored pro-
tein, and resides in the so-called lipid raft domains of
the outer leaflets of plasma membranes, in endosomes,
and in lysosomes [1]. An electron microscopic analysis
showed the distribution of PrP
C on the plasma mem-
branes of dendrites and spines, as well as in dendritic
transport vesicles, endosomes, the axolemma, axonal
transport vesicles and the myelin sheath [5]. Its physio-
logical functions remain unknown, but it is proposed to
be involved in cell-to-cell recognition, signal transduc-
tion by coupling with certain transmembrane-type
receptors, response to oxidative stress, or the uptake of
metal ions into cells [6]. Nevertheless, the observation
that prnp
-/- mice are viable [7] indicates the functional
redundancy of PrP
C, and raises the question of whether
a ‘loss-of-function’ of PrP
C is responsible for the neuro-
nal cell death [8]. It is equally unclear whether PrP
Sc
triggers neuronal cell death [8]. To understand the
molecular neuropathology of prion diseases, microarray-
based gene expression profiling has been conducted in
murine models [9-13] and in cultured cells infected with
the scrapie agent [14]. Proteomic analysis also identified
54 proteins differentially expressed in prion-infected cul-
tured cells [15]. However, DNA microarray-based
approaches [9-14] cannot detect the post-translational
modifications of proteins, and the proteomic analysis in
cultured cells [15] focused on the quantitative changes
of proteins rather than their post-translational
modifications.
In this study, we conducted a proteomic analysis of the
brain in a murine model of scrapie to explore the mole-
cular neuropathology of prion disease, and identified a
truncated form of collapsin response mediator protein-2
(CRMP-2). Liquid chromatography-electrospray ioniza-
tion-tandem mass spectrometry (LC-ESI-MS/MS)
revealed that the truncation occurred on the carboxylic
side of Ser
517. CRMP-2, also known as CRMP-62, dihy-
dropyrimidinase-related protein 2, Unc-33-like protein,
or TOAD-64 [16-19], is a mediator of axonal outgrowth
and axon-dendrite specification [16-20], and its activity is
regulated through the sequential phosphorylation of its
carboxyl-terminal (C-terminal) region by Cdk5 and GSK-
3b or by Rho-kinase [20]. As the truncation at Ser
517
caused the partial ablation of the C-terminal phosphory-
lation sites, we further examined if the truncation affects
the morphology of neurites in primary cultured neuronal
cells.
Results
Two-dimensional electrophoresis of the soluble fractions
from brain homogenates
Female C57BL/6J and ICR mice inoculated intracere-
brally with prion (Obihiro-I strain) [21] began to show
symptoms at approximately 130 days after inoculation
(dai), fell ill by 170 dai, and were euthanized by 190 dai
having entered the terminal stage. The accumulation of
PrP
Sc in the brain became detectable by Western blot-
ting at approximately 100 dai and was obvious from 130
dai (see below), as previously reported [22]. By contrast,
the mock-infected control mice were healthy throughout
the experiment. Using two-dimensional electrophoresis
(2-DE) analysis and matrix-assisted laser desorption/
ionization-mass spectrometry (MALDI-MS) (C57BL/6J
sacrificed at 40, 69, 101, 133, and 160 dai, n = 2; ICR at
32, 70, 116, and 152 dai, n = 3), we found increases in
the levels of glutathione S-transferase-μ1 and peroxire-
doxin-6 (Figures 1A, B, and 1C, spots 4 and 5, respec-
tively; Table 1). We also detected an increased
abundance of glial fibrillary acidic protein (GFAP) in the
infected mice (Figure 1B, spots 1-3; Table 1), as pre-
viously reported [9-11,13,23,24].
During the analysis, we were particularly interested
in spots a, b1, b2,a n db3, named according to their
acidic or basic pI values (Figure 1). The intensity of
spot a increased with the progression of the disease in
ICR mice (Figure 1B) and C57BL/6J mice (not shown),
whereas the intensity of spots b1, b2,a n db3 decreased
(Figure 1B). We also found that the intensity corre-
sponding to spot a remained very weak in the mock
control mice (Figure 1D). MS analysis demonstrated
that spots a, b1, b2,a n db3 invariably contained
CRMP-2 (Table 1). This result was further confirmed
by Western blot analysis with an anti-CRMP-2 anti-
body (C4G) (Figure 1E). The antibody revealed several
additional spots undetectable by SYPRO Ruby staining
due to their low abundance (compare Figures 1D and
1E). These spots appeared to reflect the diverse levels
of phosphorylation because each spot was separated by
an almost constant pI value that was indicative of pro-
tein phosphorylation [25,26], and because treatment
with l-phosphatase (l- P P a s e )[ 2 7 ]p r i o rt ot h e2 - D E /
Western blot analysis eliminated the spots in the acidic
region (Figure 1E, top and bottom). Spot b1 had an
observed molecular mass (Mrobs)o f6 1k D aa n dp I
(pIobs)o f5 . 7 7( T a b l e1 )t h a tw e r ec l o s et ot h et h e o r e -
tical Mr (62,278 Da) and pI (5.95) of the non-
phosphorylated full-length CRMP-2. On the other
hand, spot a had an Mrobs of approximately 56 kDa
and a pIobs of 5.45 (Table 1), and the l-PPase treat-
ment did not affect its electrophoretic mobility (com-
pare Figure 1E, top and bottom).
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Page 2 of 12Structural elucidation of the 56-kDa form of CRMP-2 by
LC-ESI-MS/MS
To elucidate the structure of CRMP-2 in spots a (56
kDa) and b1 (61 kDa), we compared the tryptic peptides
derived from the two spots by LC-ESI-MS/MS (Figure
2). In addition to the peptides detected in both digests
(Figure 3, shown in grey), spot b1 yielded C-terminal
peptides (Figure 3, indicated by boxes) including Ile
558-
Arg
565 ([M+H]
+ = 766.5), Glu
526-Arg
532 ([M+H]
+ =
778.5) (Figure 2A, an asterisk at 13.2 min), and Ala
566-
Gly
572 ([M+H]
+ = 675.3) (Figure 2A, an asterisk at 17.5
min). Recovery of these C-terminal peptides, together
with the Mrobs (61 kDa), indicated that CRMP-2 in spot
b1 was the full-length form. Conversely, the digest
derived from spot a did not yield these C-terminal pep-
tides (Figure 3). We then digested CRMP-2 in spots a
and b1 using endoproteinase Glu-C (Glu-C) (Figure 2B).
Full-length form of CRMP-2 is expected to release the
C-terminal fragment Val
506-Asp
547 (broken line in Fig-
ure 3) on digestion with Glu-C. However, this peptide
Figure 1 Two-DE analysis of soluble brain fractions. (A and B) CBB-stained gel obtained from a prion-infected ICR mouse (152 dai), and
magnified images of boxes I-IV. The numbered spots differed in signal intensity between the prion-infected mice and the mock-infected
controls, and were identified as listed in Table 1. (C) SYPRO Ruby-stained gel obtained from a prion-infected C57BL/6J mouse (160 dai). (D) The
magnified image of the boxed area in (C) in comparison with the corresponding area of a 2-DE gel from a control C57BL/6J mouse. (E) Western
blot analysis using the C4G anti-CRMP-2 antibody on the corresponding samples in (D). The lower panel shows the sample pre-incubated with
l-PPase.
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Page 3 of 12was not detected in the digest of spot a;i n s t e a d ,t h e
digest of spot a but not spot b gave rise to a unique
peak in the chromatogram (an asterisk at 25.2 min in
Figure 2B). MS analysis of this peak fraction detected
three ion peaks at m/z values of 594.4, 913.7, and
1186.8 (Figure 2B). Subsequent LC-ESI-MS/MS analysis
determined that the ion peaks at m/z 1186.8 ([M+H]
+)
and 594.4 ([M+2H]
2+) were derived from the peptide
Val
506-Ser
517 (Figure 2D), while the ion peak at m/z =
913.7 ([M+H]
+) was ascribed to a b-type ion of Val
506-
Thr
514 (Figure 2C). This b-type ion may be produced by
the fragmentation of the parental peptide Val
506Ser-
ValThrProLysThrValThr
514Pro
515AlaSer
517 between the
Thr
514-Pro
515 bond, such a fragmentation between -X
n–
Pro
n+1- to release bn and yN-n ions (Gly and Pro are
unfavorable for X, N is the total number of amino acids)
being observed in tandem MS [28]. Because Glu-C
hydrolyzes Glu-X and Asp-X bonds, the presence of a
Ser residue at the C-terminus strongly suggested that
the peptides were originally at the C-terminus of
CRMP-2 in spot a. In support of this, the values of
Mrobs and pIobs of spot a were in good accord with the
corresponding theoretical values for non-phosphorylated
CRMP-2
1-517 (Table 1). Therefore, we concluded that
the 56-kDa CRMP-2 in spot a was truncated at Ser
517,
and designated this shortened form CRMP-2-ΔC.
The ratio of CRMP-2-ΔC to full-length CRMP-2 during the
progression of prion disease
Completion of the structural analysis of CRMP-2-ΔC
enabled us to use the N3E antibody to evaluate the rela-
tive amounts of CRMP-2-ΔC( 5 6Da) and the full-
length form (61 Da). Since the full-length CRMP-2
and CRMP-2-ΔC both contain the epitope for the N3E
antibody which recognizes the amino acid sequence
142-194 of CRMP-2 [29], the antibody should give com-
parable signal intensities of the two forms in Western
blot analysis. We observed that the ratio of the amount
of CRMP-2-ΔC (56 kDa) to the total amount of CRMP-
2 (56 kDa + 61 kDa) was negligible at 40, 69, and 101
dai, and increased slightly at 133 dai in the prion-
infected mice and the mock-infected controls (Figures
4A and 4B). In the controls sacrificed at 160 dai, the
ratio increased in a narrow range and did not exceed
0.3 (Figure 4B, right). By contrast, in the prion-infected
mice sacrificed at 160 dai when the expression of GFAP
was up-regulated (Figure 4A), CRMP-2-ΔC increased
moderately whereas the full-length form decreased. As a
Table 1 Summary of the mass spectrometry analysis
2-DE
b) Mass spectrometry Theoretical
b) Fold
change
d)
(160dai)
p
e)
Spot
a) Mrobs
(kDa)
pIobs Method Identity UniProt KB
accession
Coverage Number of
peptides
Mowse
score
c)
Mrcal
(kDa)
pIcal
a 56 5.45 MALDI &
LC-ESI
CRMP-2-ΔC O08553 39 17 963 56.5
f) 5.48
f) 7.96 0.076
b1 61 5.77 MALDI &
LC-ESI
CRMP-2 O08553 45 22 1419 62.3
g) 5.95
g) 0.53 0.375
b2 61 5.72 MALDI &
LC-ESI
CRMP-2 O08553 8 4 61 62.3 5.95
h) 0.39 0.249
b3 61 5.68 MALDI &
LC-ESI
CRMP-2 O08553 7 4 103 62.3 5.95
h) 0.51 0.350
1 43 5.1 MALDI GFAP P03995 39 13 79 49.9 5.28 0.85 0.823
2 41 5.02 MALDI GFAP P03995 48 18 155 49.9 5.28 1.33 0.628
3 40 4.85 MALDI GFAP P03995 25 9 66 49.9 5.28 8.93 0.056
4 27 7.4 LC-ESI Glutathione S-
transferase μ1
P10649 21 7 176 25.8 8.14 +++
i) ND
5 26 5.79 MALDI Peroxiredoxin -6 O08709 44 8 121 24.7 5.72 1.58 0.389
6 24 5.02 LC-ESI Peroxiredoxin -2 Q61171 38 8 372 21.6 5.2 0.90 0.850
a) The spots shown in Figure 1.
b) Mrobs and Mrcal, observed and theoretical Mr; pIobs and pIcal, observed and theoretical pI, respectively.
c) Probability-based Mowse score [52] calculated using MASCOT software [48].
d) Fold change of spot volume on 160 dai.
e) p-Value of Student’s t-test. ND: not determined.
f) Mrcal and pIcal of non-phosphorylated CRMP-2
1-517.
g) Mrcal and pIcal of non-phosphorylated CRMP-2
1-572.
h) An approximate shift of -0.05 per phosphate moiety is expected [25,26].
i) Undetectable in the mock sample.
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Page 4 of 12Figure 2 Structural analysis of CRMP-2. (A) Total ion chromatograms of tryptic digests derived from spots a (blue) and b1 (black). The peaks
with asterisks were detectable in the digest of spot b1, but not spot a. Lower panels show the MS spectra of the fractions eluted at 13.2 min
and 17.5 min, and the amino acid sequences determined by LC-ESI-MS/MS. (B) Total ion chromatograms from the Glu-C digest of spots a (blue)
and b1 (black). The peak with an asterisk was detectable in the digests of spot a, but not spot b1. Lower panels show the MS spectra of the
fraction eluted at 25.2 min, and the determined amino acid sequences. (C) LC-ESI-MS/MS spectrum and the sequence of the parental ion of m/z
= 913.7. This parental ion was the b9 ion with a loss of a hydroxyl (-OH) group. The gain of the detector was modulated as indicated (× 2 or ×
20 amplification) to optimize data acquisition. (D) MS/MS spectrum and the sequence of the parental ion of m/z = 1186.8.
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to those observed for the full-length form of CRMP-2
(Figure 4B, left). This change of CRMP-2-ΔC in the late
stages of the disease was further confirmed by the
examination of an additional number of specimens
(Additional file 1). This modest but statistically signifi-
cant change appeared to account for the focal distribu-
tion of lesions in the brain [1-3].
Analysis of the CRMP-2 transcript
Two variant forms of CRMP-2, named CRMP-2A and
-2B, were previously identified that had different amino
terminal regions due to the alternative usage of two first
coding exons [30-33]. Therefore, we examined if the
occurrence of CRMP-2-ΔC was due to alternative spli-
cing or post-translational processing. Using Northern
blot analysis, a single 4.5-kb band was invariably
detected in the prion-infected mice (n = 2) and the
mock controls (n = 2) sacrificed at 160 dai (Figure 4C).
T h i ss i z ew a ss u b s t a n t i a l l yt h es a m ea sf o rt h ep r e -
viously reported CRMP-2 gene transcript [17,19];
accordingly, we conceived that CRMP-2-ΔCw a sn o t
produced by alternative splicing, but by post-transla-
tional proteolytic cleavage. It should be noted that den-
sitometric analysis of the bands did not show significant
difference in the mRNA levels of CRMP-2 between the
prion-infected and the control mice after normalization
to the amount of glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) mRNA (Figure 4C, right). In a further
analysis by quantitative RT-PCR to compare the mRNA
levels of CRMP-2 in the two groups of mice in detail,
we again did not find a statistical difference in the level
of CRMP-2 mRNA between the prion-infected mice and
the mock controls (Additional file 2).
Effects of the overexpression of CRMP-2-ΔC on neurons
in vitro
Considering the increasing ratio of CRMP-2-ΔC to full-
length CRMP-2 in the late stages of prion disease in our
model (Figure 4), we asked whether CRMP-2-ΔCw o u l d
affect the morphology of the neurites. Plasmids encoding
full-length CRMP-2 (named CRMP-2-wt), CRMP-2-ΔC,
or phosphorylated or non-phosphorylated mimics named
CRMP-2/DD, /AD, /DA, and /AA, in which the C-term-
inal potential phosphorylation sites Thr
514 and Thr
555
[20] were mutagenized to Asp or Ala (Figure 5A),
were introduced into murine embryonic cerebral neu-
rons on the first day of culture in vitro (0-DIV). As
the transfection efficacy of the neurons in primary cul-
ture was rather low, we co-transfected a plasmid
encoding green fluorescent protein (GFP) to identify
the transfected cells. The cells positive for GFP-fluores-
cence were examined at 4-DIV for neurites longer than
10 μm, and we found that the cells transfected with
CRMP-2-ΔC developed 1.2-fold more neurite tips than
the cells transfected with the empty vector (Figures 5B
and 5C). An enhanced level of branching of the neur-
ite tips was also observed in the cells expressing the
non-phosphorylated mimic CRMP-2/AA (Figures 5B
and 5C). Conversely, the cells transfected with CRMP-
2-wt exhibited slightly fewer neurite branch tips than
the cells transfected with the empty vector, similar to
the cells transfected with CRMP-2/DD (Figures 5B and
5C). This was presumably because cellular kinases
phosphorylated CRMP-2-wt that, in turn, acted against
the development of neurite tips. In contrast to the
range of variation in branching, the length of the long-
est neurites did not show a significant difference and
were in the range of 269.8 ± 10.1 μm (Figure 5D).
Figure 3 Summary of the LC/MS analysis. Gray: detected in the tryptic digests of both spots a and b1; white box: detected in the tryptic
digest of spot b1; red underline: detected in the Glu-C digest of spot a ([M+H]
+ = 1186.8); blue underline: detected in the Glu-C digest of spot
a ([M+H]
+ = 913.7); broken underline: expected to be obtained by the Glu-C digestion of full-length CRMP-2; *: the potential phosphorylation
sites. The sequence is from UniProtKB; O08553.
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CRMPs are cytosolic phosphoproteins abundantly
expressed in the developing brain [16-20,31], and in
some neurons and oligodendrocytes in the adult brain
[17,19,32,33]. Among the five known isoforms (CRMP-1
to -5), CRMP-2 was originally identified as a mediator
of the collapse of growth cones by semaphorin [16], and
later shown to be involved in the outgrowth of axons
and the induction of neuronal polarity [20] in develop-
ing neurons. Further studies also showed different spli-
cing patterns of its mRNA, giving rise to two variant
forms named CRMP-2A and -2B [30]. CRMP-2A (theo-
retical Mr of 75 kDa) has a long N-terminal sequence,
and induces oriented microtubule patterns in cultured
fibroblasts [30]. On the other hand, the shorter variant
CRMP-2B (theoretical Mr of 62 kDa) corresponds to
the originally identified CRMP-2 protein, and favors dis-
oriented microtubule patterns in the fibroblasts [30].
Thus, the two variants seem to display different, or even
opposite functional properties [30,32]. Intriguingly, Wes-
tern blot analysis of the brain of mouse [32] and rat [33]
showed that CRMP-2A is mainly expressed in the devel-
oping brain while CRMP-2B is predominantly expressed
in the adult brain. The temporal expression pattern of
the two forms, together with their distinct functions,
suggest that CRMP-2 plays roles more than the axonal
outgrowth and the induction of neuronal polarity.
Not only in the physiological neuronal processes, the
importance of CRMP-2 in the adult brain under non-
physiological conditions has also been implied recently
in animal models of neurodegenerative disorders includ-
ing traumatic brain injury and cerebral ischemia (see
below). Here, we performed a proteomic analysis of the
brains of mice infected with scrapie prion, and found a
C-terminally truncated form of CRMP-2 (CRMP-2-ΔC)
in the late pathological stages of the disease. To date,
truncated forms of CRMP-2 have been identified in cul-
tured neurons exposed to N-methyl-D-aspartic acid
[34,35] or depleted of nerve growth factor [36], in mod-
els of traumatic brain injury [35,37], ischemia [38], and
sciatic nerve injury [39], and in the developing mouse
brain [31]. Although the precise cleavage sites of
CRMP-2 in these studies remain undetermined,
sequence-specific antibodies [34,35] or peptide mapping
in MS analyses [31,36,39] mapped them to the C-
terminal region. In addition, some studies ascribed pro-
teolytic cleavage by calpain to the production of the
truncated forms of CRMP-2 [34-36]. We demonstrated
that the production of CRMP-2-ΔCw a sn o td u et ot h e
alternative splicing of its mRNA, the known splicing
responsible for the production of CRMP-2A and -2B
[30]. Rather, judging from its Mrobs,p I obs and the trun-
cation site, it is most conceivable that CRMP-2-ΔCw a s
derived from proteolytic cleavage of CRMP-2B (referred
to as the full-length form of CRMP-2 in the present
study) which is predominantly expressed in the adult
brain [32,33]. We speculate that calpain is likely to be
involved in its generation, since the truncation site of
Figure 4 CRMP-2-ΔC in the brains of C57BL/6J mice during the
progression of prion disease. (A) Western blot analysis for CRMP-
2, GFAP and GAPDH. The accumulation of PK-resistant PrP
Sc is
shown at the bottom. p: prion-infected; m: mock controls. The
ladders of GFAP bands are possibly due to post-translational
cleavage [24] or alternative splicing [51]. (B) The amounts of 61-kDa
and 56-kDa CRMP-2 relative to the total amount of CRMP-2 as
determined from the signal intensity of the bands in panel (A). Data
are means ± SEM (n = 2). (C) Northern blot analysis for prion-
infected and mock-infected mice sacrificed at 160 dai (n = 2,
respectively). The arrowhead indicates the CRMP-2 transcript. The
ratios of signal intensities of the bands of CRMP-2 mRNA to that of
GAPDH mRNA are shown after normalization to the ratio obtained
from the control mice as 1.00 (means ± SEM).
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Page 7 of 12CRMP-2-ΔC( P 4 =T h r ,P 3 =P r o ,P 1’ =S e r ,a n dP 2’ =
Ala) was in modest agreement with the amino acid
sequences preferred for cleavage by calpain [40,41]. In
this regard, an increased level of μ-calpain was reported
in the hippocampus of prion-infected mice [24]. It
should be noted that a recent quantitative RT-PCR ana-
lysis of the brains of C57BL/6 mice challenged with
bovine spongiform encephalopathy prion showed an
increased level of CRMP-2 mRNA approximately to
140% of that in the control mice in the mid-stage of the
disease, and its decrease to 54% in the terminal stage
[42]. We have shown the level of CRMP-2 mRNA did
not differ significantly between the prion-infected and
the control mice in the late phase of the disease (Figure
4C, Additional file 2). The reason for this discrepancy in
the decreased level of CRMP-2 mRNA in the later
stages of the disease remains unknown at the moment.
It might be due to the difference in the prion strains, or
the difference in the pathological severity at the timing
of the specimen sampling. The truncation of CRMP-2
was not mentioned in this transcriptional study [42].
Lines of evidence to date indicate that the sequential
phosphorylation of CRMP-2 at Ser
522,T h r
509,T h r
514
and Ser
518 by Cdk5 and GSK-3b is essential for the reg-
ulation of CRMP-2 activity [20,29]. These regulatory
sites are, however, partially ablated in CRMP-2-ΔC. In
fact, the unchanged pI value of CRMP-2-ΔC after incu-
bation with l-PPase (Figure 1E), and the absence of a
neutral loss of H3PO4 (Δm/z = -98) in the MS analysis
of CRMP-2-ΔC (data not shown), strongly indicated
that it was not phosphorylated. Thus, the augmentation
in the development of neurite branch tips of cultured
neurons by the overexpression of CRMP-2-ΔCm a yb e
explained by the lack of the regulatory phosphorylation
sites. Alternatively, it is recognized that CRMPs are
assembled into homo- or hetero-tetramers. Interestingly,
while the structure of the recombinant CRMP-2
13-490
(i.e., lacking the C-terminal region) was indeed in a
Figure 5 Effect of CRMP-2-ΔC on primary cultured neurons. (A) Diagram of the cDNA constructs. The asterisks show the potential
phosphorylation sites in the C-terminal region. (B) Representative images of the neurons at 4-DIV. Bar; 20 μm. (C) Numbers of neurite branch
tips longer than 10 μm in individual cells at 4-DIV. Data are means ± SEM from at least 24 cells.
*Statistical difference determined by Student’st -
test (P0.05). (D) Lengths of the longest neurites of the cells at 4-DIV. Data are means ± SEM of the lengths from at least 24 cells.
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Page 8 of 12tetrameric form, as determined using crystallographic
analysis, it behaved like a trimer when analyzed using gel
filtration [43]. This was interpreted to indicate a rapid
equilibrium between the tetrameric and the dimeric
states of CRMP-2
13-490 [43]. If so, it is conceivable that
CRMP-2-ΔC has a reduced ability to undergo oligomeri-
zation. Such a defect in oligomerization into the homo-
meric and/or heteromeric state would impair the
physiological function of CRMP-2. In the adult brain,
CRMP-2B is the predominant form of CRMP-2, and
mainly localizes in dendrites [32]. Considering that ham-
ster [2] and murine [3] models of scrapie showed neuro-
nal dendritic atrophy before ultimate neuronal cell death,
it is interesting to surmise that CRMP-2-ΔCm i g h tb e
involved in such a neurodegenerative process.
Conclusions
To explore the molecular neuropathology of prion dis-
eases, we conducted a proteomic analysis of a murine
model of prion diseases. In addition to the quantitative
changes of GFAP, glutathione S-transferase-μ1a n dp e r -
oxiredoxins during the progression of the disease in the
brain of ICR and C57BL/6J mice, we identified a unique
truncation of CRMP-2. Detailing the relevance of
CRMP-2-ΔC to the morphological abnormalities of
degenerating axon terminals/dendrites observed in mod-
els of scrapie [1-3] awaits further study. Nevertheless,
considering that several forms of truncated CRMP-2, if
not identical to CRMP-2-ΔC, were found in models of
neurodegenerative disorders [35-39], the results of the
present study should provide clues to the molecular
neuropathology of prion diseases compared with other
neurodegenerative disorders.
Methods
Mice, prion inoculation, and brain homogenate
Female C57BL/6J and ICR mice (6 weeks old) were pur-
chased from Charles River Laboratories (Yokohama,
Japan) and CLEA Inc. (Meguro, Japan), respectively. The
mice were inoculated with 25 μLo fa0 . 2 5 %( w / v )b r a i n
homogenate in phosphate-buffered saline (PBS; JRH
Biosciences, Lenexa, USA) prepared from terminally ill
ICR mice infected with mouse-adapted scrapie prion
(Obihiro-I strain) [21]. As mock-infected controls, mice
were injected with 25 μL of a 0.25% brain homogenate
(w/v in PBS) from healthy mice. Experiments were car-
ried out in compliance with the biosafety regulations
and the guidelines for laboratory animal care of the
National Institute of Infectious Diseases. Individual
brains were homogenized in 4-volumes (w/v) of chilled
PBS using a Physcotron homogenizer (Microtec Co.,
Ltd., Funabashi, Japan), and centrifuged at 100,000 × g
for 1 h at 4°C with a TLA-55 rotor (Beckman Coulter,
Inc., Fullerton, USA) to obtain the supernatant (soluble
fraction) and the pellet (membranous fraction). Protein
concentrations were determined using a BCA protein
assay kit (Pierce, Rockford, USA).
2-DE
The samples were prepared by adjusting the soluble frac-
tion of the brain homogenate to a total of 400 μgp r o -
tein/mL in 9 M Urea, 4% CHAPS, 65 mM DTT, and
0.5% IPG buffer 3-10 (GE Healthcare, Uppsala, Sweden).
Immobiline DryStrips for isoelectric focusing (IEF; pH 3-
10 NL, 13 cm, GE Healthcare) were rehydrated at 20°C
overnight by soaking in 250 μL of the sample solution (a
total of 100 μg of protein), then IEF was carried out using
a linear gradient from 0-1000 V in 2 h, followed by 8000
V for 6 h. After IEF, the strips were equilibrated with 50
mM Tris-HCl (pH 8.8), 6 M urea, 2% SDS, 20 mM DTT,
30% glycerol, and 0.03% bromophenol blue for 15 min,
and overlaid on 12.5% polyacrylamide slab gels for SDS-
PAGE. Proteins were stained with CBB R-250 or SYPRO
Ruby (Invitrogen, Carlsbad, USA), and gel images were
captured using a LAS-1000 plus lumino-image analyzer
(Fuji Photo Film, Tokyo, Japan). Software PDQuest, ver-
sion 7.3 (Bio-Rad Laboratories, Hercules, USA) was used
for the image analysis. At least one duplicate set of mice
was analyzed for each specified dai. Mr and pI were cali-
brated using the spots of the following proteins: calmo-
dulin (16.7 Da, pI 4.1), g-enolase (47.2, 5.0), serum
albumin (65.9, 5.5), peroxiredoxin 6 (24.7, 5.72), carbonic
anhydorase II (28.9, 6.5), and aconitase (82.5, 7.4). The
signal intensity of each spot was normalized to that of b-
actin for statistical analysis. In the dephosphorylation
analysis, the samples were incubated with l-PPase (New
England Biolabs, Inc., Beverly, USA) at 30°C for 15 min
prior to 2-DE.
Western blotting
The anti-CRMP-2 antibodies C4G (epitope; CRMP-2
480-528)
and N3E (epitope; CRMP-2
142-194) [29] were purchased
from Immuno-Biological Laboratories Co., Ltd. (Taka-
saki, Japan). The other antibodies used were anti-GFAP
(DAKO, Glostrup, Denmark), anti-GAPDH from (Abcam
plc., Cambridge, UK), HRP-labeled anti-mouse IgG
(TrueBlot) (eBioscience Inc., San Diego, USA), and HRP-
labeled anti-rabbit IgG F(ab’)2 (GE Healthcare). The ECL
Plus reagent (GE Healthcare) and a LAS-3000mini
lumino-image analyzer (Fuji Photo Film) were used for
detection. Signal intensity was quantified using Image
G a u g es o f t w a r e( F u j iP h o t oF i l m ) .F o rt h ea n a l y s i so f
PrP
Sc, the membranous fraction (a total of 10 μgp r o -
teins) in 30 μL of 0.5% sarkosyl, 25 mM Tris-HCl, and 50
mM NaCl (pH 7.5) was incubated with PK (final concen-
tration, 0.1 μg/μL) at 37°C for 120 min. The digestion
was stopped by the addition of 4-volumes of 10 mM phe-
nylmethylsulfonyl fluoride in methanol, and the mixture
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PrP
Sc as a precipitate. The anti-PrP monoclonal antibody
4 4 B - 1[ 4 4 ]w a sag i f tf r o mP r o f .M .H o r i u c h i( H o k k a i d o
University, Japan).
MS and protein identification
Pieces of the 2-DE gel were rinsed with 100 mM ammo-
nium bicarbonate, and incubated with 10 mM DTT at
56°C for 45 min. Then, protein in the gel was reacted
with 55 mM iodoacetamide at room temperature for
45 min, and subjected to in-gel digestion [45,46] with
trypsin (sequencing grade; Promega, Madison, USA) or
Glu-C (EC 3.4.21.19; Roche Applied Science, Basel,
Switzerland). For the peptide-mass fingerprint analysis,
MS data for the tryptic digests obtained with a Voyager-
DE STR spectrometer (Applied Biosystems, Foster City,
USA) were examined in the NCBInr.fasta protein data-
base using MS-Fit [47] and Mascot/version 2.1 (Matrix
Science, Boston, USA) software [48]. For the amino acid
sequence analysis of CRMP-2, the digests were applied
to a MAGIC2002 HPLC system (Michrom Bioresources,
Inc., Auburn, USA) equipped with a capillary column
(Inertsil ODS 3 μm, 0.1 mm i.d. × 50 mm, GL Science
Inc., Shinjuku, Japan). Elution was performed using (A)
H2O/acetonitrile/formic acid = 98/2/0.1 (v/v/v) and (B)
H2O/acetonitrile/formic acid = 10/90/0.1 (v/v/v), with a
gradient from A/B = 95/5 (v/v) to 45/55 (v/v) at a flow
rate of 400 nL/min. The eluate was introduced into an
LCQ Deca XP spectrometer (Thermo Fisher Scientific
Inc., Waltham, USA) using a nano-ESI interface (AMR
Inc., Meguro, Japan) and a MonoSpray FS monolithic
emitter (GL Sciences). The data were collected at an
interval of three tandem spectra per spectrum in the
data-dependent-scan mode, and analyzed using Bio-
Works software (Thermo Fisher Scientific Inc., version
3.1) and by manual inspection. The theoretical Mr and
pI values were calculated using Compute pI/MW [49]
and Scansite [50] software.
Northern blotting
RNA was prepared from the whole brains of C57BL/6J
mice sacrificed at 160 dai using the SV Total RNA
Isolation System (Promega), and stored at -80°C in
RNAsecurer e a g e n t( A p p l i e dB i o s y s t e m s )u n t i lu s e .E l e c -
trophoresis was carried out with 1 μgo fR N Au s i n g
1.0% agarose-formaldehyde gel in 40 mM MOPS-NaOH,
10 mM sodium acetate, and 1 mM EDTA (pH 7.0).
After the transfer of the RNA to a positively charged-
nylon membrane (Roche Applied Science), the mem-
brane was incubated with digoxigenin-labeled antisense
RNA probes for CRMP-2 (complementary to the open
reading frame (ORF) from +340 to +1551; correspond-
ing to Thr
114-Ser
517) or GAPDH (the ORF of from +330
to +878) at 68°C overnight in Ambion ULTRAhyb
hybridization buffer (Applied Biosystems). The bound
probes were detected using an alkaline phosphatase-
labeled anti-digoxigenin antibody (Roche Applied
Science) and CDP-Star chemiluminescence reagent
(New England Biolabs, Inc.), with X-ray films (Fuji
Photo Film) and a LAS-3000mini lumino-image analyzer
(Fuji Photo Film). Signal intensity was quantified using
Image Gauge software (Fuji Photo Film).
Plasmids
Full-length cDNA of mouse CRMP-2-wt was obtained
from a C57BL/6J mouse brain cDNA library (Invitrogen)
by PCR using the following primers: 5’- GGAATTCGA-
GATGTCTTATCAGGGGAAGAAAAATATTCCA-3’
and 5’- ATAAGAATGCGGCCGCTTTAGCCCAGGCT
GGTGATGTTGG-3’ (the underlined sequences are for
the generation of EcoRI and NotIs i t e s ) .C R M P - 2 - ΔC
cDNA (CRMP-2
1-517) was generated using the reverse
primer 5’-A T A A G AA T GCGGCCGCTTAT-
GAGGCTGGAGTCACC-3’ (the underlined sequence is
for the introduction of a NotI site). The cDNAs were
ligated into the pCIneo mammalian expression vector
(Promega) between the EcoRI and NotI sites. Site-direc-
ted mutagenesis was carried out using the following pri-
mers: 5’- GTGACGCCCAAGACGGTGGCGCCAGCCT
CATCAGCTAAG-3’ and 5’- CTTAGCTGATGAGGCT
GGCGCCACCGTCTTGGGCGTCAC-3’ for T514A; 5’-
GTGACGCCCAAGACGGTGGATCCAGCCTCATC
AGCTAAG-3’ and 5’- CTTAGCTGATGAGGCTG
GATCCACCGTCTTGGGCGTCAC-3’ for T514D; 5’-
CATTCCCCGCCGCACCGCCCAGCGCATCGTGG-3’
and 5’-C C A C G A T G C G C T G GGCGGTGCGGCGGG
GAATG-3’ for T555A; and 5’- CATTCCCCGCCG-
CACTGATCAGCGCATCGTGG-3’ and 5’-C C A C
GATGCGCTGATCAGTGCGGCGGGGAATG-3’ for
T555D. The constructs were verified using DNA
sequencing.
Cell culture, transfection, and microscopy
Cerebral cortical neurons from E15 ICR mice (Nerve-cell
Culture System; Sumitomo Bakelite Co., Ltd., Shinagawa,
Japan) were plated on poly-L-lysine-coated plastic dishes
(Sumitomo Bakelite Co., Ltd.), and maintained in Neu-
robasal medium (Invitrogen-GIBCO) with B27 (Invitro-
gen-GIBCO) and 0.5 mM glutamine according to the
manufacturer’s instructions. Arabinocytidine (2.5 μM)
was added to the medium to suppress the growth of
glia. The pCIneo vectors encoding CRMP-2 or its
mutants (1 μg) were mixed with pEGFP-N1 encoding
GFP (0.5 μg; Clontech Laboratories Inc., Mountain
View, USA), and the mixture was introduced into cells
using the NeuroPORTER transfection reagent (Genlantis,
S a nD i e g o ,U S A )a tt h et i m eo fp l a t i n g( 0 - D I V ) .T h e
neurons were fixed at 4-DIV using BD Cytofix (BD
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Page 10 of 12Biosciences, Franklin Lakes, USA) for 15 min at room
temperature, and observed under a BIOZERO BZ-8000
microscope (Keyence, Osaka, Japan) with a software BZ
analyzer (Keyence) for counting the number of neurite
tips and measuring the length of neurites.
Additional material
Additional file 1: CRMP-2-ΔC in the brains of C57BL/6J mice in the
late stages of the disease. A supplementary data of Western blot
analysis for detection of CRMP-2-ΔC in additional individuals of prion-
infected and mock control mice.
Additional file 2: Relative levels of CRMP-2 mRNA determined by
quantitative RT-PCR. The mRNA levels of CRMP-2 did not show
significant difference between the prion-infected and mock control mice
in quantitative RT-PCR analysis.
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